2018-07-052016-05-06ARAÚJO, Deize Evangelista. Avaliação do potencial in vitro e in vivo de tiossemicarbazida, tiossemicarbazida em nanopartícula de quitosana e tiossemicarbazida derivada do canfeno como antifúngico sobre Candida albicans. 2016. 91 f. Dissertação (Mestrado em Genética e Biologia Molecular) - Universidade Federal de Goiás, Goiânia, 2016.http://repositorio.bc.ufg.br/tede/handle/tede/8656Candidiasis is a serious health problem that affects a large number of people arround the world. The treatment of this disease is carried out with antifungals, which do not provide an effective cure, besides having resistance reports and high toxicity. In this context, it is necessary to study new antifungal compounds. In addition, the delivery form of the compounds in the living organism is also target of research, since the controlled release of compounds in biological systems can improve the mode of action of many drugs. Therefore, nanostructured systems, such as nanoparticles of chitosan, have been widely studied as controlled delivery of drugs. Then, this study aimed to evaluate the antifungal potential against Candida albicans of thiosemicarbazide (TSC), thiosemicarbazide-camphene (TSC-C) and chitosan nanoparticles incorporated with thiosemicarbazide (nanoTSC). In in vitro assays, the compounds were effective to inhibit nearly 100% of the fungus in concentrations of 1,37 mM to TSC, 0,02 mM to TSC-C and 0,27 mM to nanoTSC, and the most effective compound was TSC-C. NanoTSC and empty nanoparticles were also evaluated as to cell toxicity, and the concentration able to inhibit the fungus showed no cytotoxic activity. To confirm the values observed in in vitro assays, experiments were conducted using an animal model for vulvovaginal candidiasis. The results showed that TSC-C was more efficient in inhibiting C. albicans compared with TSC and nanoTSC, but was less effective than miconazole. However, histopathological analysis showed that the groups treated with the compounds under study, showed less intensity of damage to the vaginal epithelium and inflammatory infiltrates, compared with the positive control and the group treated with miconazole. Thus, the results suggest that TSC, nanoTSC and TSC-C are promising compounds in the treatment of vulvovaginal candidiasis.application/pdfAcesso AbertoCandidíase vulvovaginalTiossemicarbazidaTiossemicarbazida-canfenoNanopartículasVulvovaginal candidiasisThiosemicarbazideThiosemicarbazide-campheneNanoparticlesCIENCIAS BIOLOGICAS::GENETICADissertação